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want harm to come to those who helped me get my results. It is my
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to what one has a right to know about oneself is not necessarily
straightforward or easy. I am happy to respond to correspondence,
which can be sent to me via the editor for this special issue: misha.
angrist@duke.edu.
Given the culture shift toward greater data sharing, I assumed that I
could have access to my genomic data and share it with whomever I
chose rather easily. I was wrong.
Not too long ago I hadmywhole exome sequenced (WES) at amajor
medical center. It seemed there was ﬁnally the opportunity to learn a
root cause for my underperforming immune system, which seemed to
outsmart every available intervention. Perhaps getting my whole
exome sequence could also help immunogenomics researchers and ul-
timately others similarly compromised.
I ﬂew to one of the country's top academicmedical centers to con-
sult with an immunologist and get sequenced. The doctor brieﬂy de-
scribed WES and I signed the consent form, opting in to receive a
focused report containing unexpected variants of clinical signiﬁ-
cance, and authorizing the laboratory to share my data with
researchers. The form was lengthy but not as clear or explicit as
the lab's online FAQ, which detailed the reporting of results and
medically actionable ﬁndings, including ACMG-categorized inciden-
tal ﬁndings and laboratory-categorized incidental ﬁndings (addi-
tional incidental ﬁndings determined by the laboratory's experts
deemed to be “medically actionable”).
When consenting, I requested the expanded report, which would
tell me about pathogenic variants and unclassiﬁed variants in genes un-
related tomy phenotype, aswell as deleteriousmutations in genes with
no currently known human disease association. Protocol required that
this report be ordered separately by the referring physician and only
after the focused report was released, though I wasn't told so.
I also asked to receivemy raw data in the form of a VCF or equivalent
ﬁle. My prescribing physician didn't knowwhat such a ﬁle was. I decid-
ed not to push the issue until results were in, which I was told would
take about 15 weeks. Seven months later my doctor hadn't received
any results, so I phoned the clinic. After parrying with the staff, I was
eventually transferred to the clinic Fellow on duty, the only one acting
as liaison with the lab since the ordering physicianwas away onmater-
nity leave.
After contacting the lab, the Fellow reported back to me. Results
could only be sent to the ordering physician (the one on extended ma-
ternity leave), and the only one authorized to send results to myhttp://dx.doi.org/10.1016/j.atg.2016.01.011
2212-0661/© 2016 The Author. Published by Elsevier B.V. This is an open access article underphysician back home. This meant I had no idea when I would receive
the results. Meanwhile, my increasingly funky immune system was
compromising my ability to function.
Notably, the Fellow did not know the policy or practice for giving
results to a patient's referring physician, let alone directly to a patient.
They could not be sent via email or fax to my physician at home, or
to me. Either of these, I was told, would violate HIPAA and/or CLIA
regulations. The results could be reported over the phone, though
we agreed that phone reporting to my physician was likely infeasible.
After much delicate pleading, including, I presume, some evidence
that I could handle unfavorable ﬁndings, the Fellow agreed to send
me the focused report. Notably, I received it via both fax and email.
The ﬁve-page ‘focused’ report contained results for 1) pathogenic
variants in disease genes related to my clinical phenotype [none
found]; 2a) likely pathogenic variants in disease genes related to my
clinical phenotype [none found]; 2b) variants of unknown signiﬁcance
(VUS) in disease genes related to my clinical phenotype [three were
noteworthy]; 3) medically actionable pathogenic variants in disease
genes related to my clinical phenotype [none found]; 4) carrier status
for recessive Mendelian disorders [none found]; and 5) relevant phar-
macogenetic alleles [one found]. The three VUS identiﬁedwere interest-
ing, if only because they were of some relation to immunity, though not
speciﬁcally informative of my phenotype. This wasmuch less than I ex-
pected, but had I been a “civilian” I feel certain I would not even have
gotten this much.
A few weeks later, I phoned to obtain my ‘extended’ report. No one
in the clinic knewwhat I was referring to. I persisted and eventually re-
ceived a nine-page report that included a tablewith: VUS possibly relat-
ed to various clinical phenotypes; their inheritance patterns; genes;
positions; isoforms; locations; nucleotide changes; amino acid zygos-
ities; references/comments; and computational predictions of pathoge-
nicity (again via both fax and email). While I was pleased to receive the
expanded report, I wanted to try to get the results in a data ﬁle that I
could upload and share. I was directed to the head of the laboratory
and told that the lab used only FASTQ and not VCF data ﬁles. More dis-
turbingly, I was told that only physicians or laboratory personnel could
access patient data ﬁles. My effort had failed. As I understood them, up-
datedHIPAA and CLIA regulations guaranteedme access tomy clinically
certiﬁed test results.1 I just wanted to know, and without a lot more
waiting or effort. I felt I had a right to know: that is, a right to the totality
of information about me. But apparently I did not.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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data is not the norm.2 But why not? Many research participants want
it.3 And a growingnumber of third-party sites arewilling to interpret it.4
But alas, genetic exceptionalism persists. I can download a radiology
report frommyEMR, print a lab test result, or even seemydoctor's sum-
mary notes. I do not see any plausible reason why I should have to ﬁght2 Lunshof, et al. Science. 2014 Jan.; 343 (6169): 373–4.
3 Middleton et al. J Med Genet. 2015 Aug.; 52(8): 571–4.
4 Angrist PLoS One. 2014 Mar. 19; 9(3): e92060; http://www.nature.com/news/
scientists-hope-to-attract-millions-to-dna-land-1.18514.so hard to getmy clinically validated genomic data. Until the data are no
longer sequestered from the person from whom they came, I′m afraid
that true “personal genomics” will remain an oxymoron.
